ANDA 211696, held by Somerset Theraps LLC. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 211696 (Fluoxetine Hydrochloride), held by Somerset Theraps LLC, was first approved by FDA on Jan 30, 2019, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2019 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| Aug 18, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 30, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters